• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Digital Health Could Serve As Valuable Asset for Pharma Industry

by HITC Staff 03/16/2018 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Patient Engagement_Pharma Marketing to Physicians

Digital health is proving to be a valuable asset for the pharma industry, as it points to a more streamlined and more cost-effective drug development process, according to GlobalData, a leading data and analytics company.

Recent years have seen a large increase in investment towards digital health – a multifaceted segment of the industry that can combine software-based therapies into various aspects of the drug development process.

Rahael Maladwala, Healthcare Analyst at GlobalData, notes: “GlaxoSmithKline recently completed a $43m deal allowing it use Exscientia’s AI platform in the drug discovery process. The digital startup will attempt to use machine learning and specifically designed algorithms to identify molecules in the body that could be potential drug targets, by predicting how they behave under certain conditions. If this method can successfully identify new drug targets, it would reduce the financial burden of pharmaceutical companies for R&D.” 

Other uses of technology in healthcare include improvements to the cost-effectiveness of clinical trials. Novartis has launched the first app-based study in multiple sclerosis that allows patients to log symptoms in real time. Meanwhile, Takeda and Lundbeck have begun using apps to monitor patients suffering from depression and how they respond to their prescribed therapies. Wearable technology is also being tested in indications that involve abnormal motor movement, such as Parkinson’s disease, multiple sclerosis, and epilepsy. The most notable examples of these include Empatica’s seizure alerting wristband, and Great Lakes NeuroTechnologies’ Kinesia 360, a sensor-smartphone app combination used to monitor Parkinson’s symptoms.

Maladwala continues: “Moving forward, this technology can be used to link clinical outcomes to real-world patient behavior, and pharma companies can develop novel endpoints – for example related to compliance in a real-world setting – that would not be possible to test in a standard clinical trial.

“As digital health is integrated more and more into the traditional drug development process, there will be challenges that need to be overcome. However, the current trends in this area all point to a more cost-effective drug development process. At a time when payer pressure aims to reduce the financial burden of healthcare for patients, this may prove invaluable for the pharma industry.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Pharma

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |